摘要 |
<p>The present invention provides a method and composition means for reducing chemotherapeutic drug resistance exhibited in-situ by a solid mass neoplasm of epithelial cell origin. The tumor cells constituting the solid neoplasm have clinically demonstrated resistance in-situ to a single- or multiple-drug treatment regimen, and the resistant tumor cells express both the PDZK1 protein and the cMOAT protein intracellularly. The invention provides antagonistic antibody preparations which inhibit the interaction of PDZK1 and cMOAT proteins intracellularly; and thereby cause a reduction in clinical resistance to the previously administered chemotherapeutic treatment agents.</p> |